Popular Articles
Cellulite Cream

MabThera To Reduce The Progression Of Joint Damage When Used As A First-line Biologic Treatment In RA
New data show for the first time that a course of 2 infusions of MabThera 1000mg (rituximab, known as Rituxan within the United States) given every 24 weeks as the patient"s first biologic can significantly slow down joint damage following 1 year of treatment, with virtually no progression of joint damage seen from six months1.
generic viagra online
El Salvador And Benin Become 1st To Order Asthma Drugs From Asthma Drug Facility (ADF)
El Salvador and Benin have marked World Asthma Day by placing orders with the Asthma Drug Facility (ADF). Through the ADF these and other low- and middle-income countries will be able to obtain quality-assured essential asthma medicines at affordable prices for the first time.
News of the day
Overall Cardiovascular Safety Of Rosiglitazone Confirmed In 5 1/2-Year Study
Results of the long-awaited Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study were presented here in a symposium at the American Diabetes Association"s 69th Scientific Sessions. The results are being simultaneously published online in The Lancet.
Health Insurance

Changing Paradigms In Hereditary Angioedema: A Focus On Timely Diagnosis And New Therapies

Hereditary angioedema (HAE) is an autosomal dominant disease affecting approximately 10,000 people in the United States. HAE causes recurrent attacks of intense localized edema involving the skin, airway, and visceral organs. While chronic therapy with attenuated androgens or plasmin inhibitors has been the mainstay of HAE therapy, many new therapies for prophylaxis and acute treatment are on the horizon. It is important for physicians to understand the signs and symptoms of patients who present with HAE and to be familiar with the conventional and emerging therapies available to treat them. To address the need for current education on HAE, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing medical education self-study audio activity titled Changing Paradigms in Hereditary Angioedema: A Focus on Timely Diagnosis and New Therapies. This activity is supported by an educational grant from ViroPharma Incorporated. Faculty for this continuing medical education activity include the following experts in allergy and immunology: Allen P. Kaplan, MD, from Medical University of South Carolina in Charleston, South Carolina; Bruce L. Zuraw, MD, from the University of California School of Medicine in San Diego, California; and Paula J. Busse, MD, from the Mount Sinai School of Medicine in New York. "Quality continuing medical education is vital to developing and increasing knowledge and skills and enhancing patient care," says Robert Michael Educational Institute LLC President and CEO, Robert M. Colleluori. RMEI is a medical education company that specializes in independent, certified and non-certified education. The goal of all certified RMEI educational offerings is to promote a spirit of lifelong learning and continuous professional development. RMEI works closely with medical experts to design activities that improve diagnosis and treatment leading to better outcomes for patients. These activities include national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs. Robert Michael Educational Institute LLC


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):